Author

Xiangxiang Wu

University of New MexicoORCID 0000-0003-3623-1161Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1

Frequent Co-Authors

Jamie L. Padilla· 2 shared Kimberly Kay LeslieiD· 2 shared Lane E. Smith· 2 shared Alexander Goss· 1 shared Daisy Belmares-Ortega· 1 shared Geneva L. WilliamsiD· 1 shared Jennifer Daw· 1 shared Josh K. Monts· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Jamie L. Padilla

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintNov 18, 2025

Curcumin Analogues Trigger HMOX1-Mediated Ferroptosis to Halt Endometrial Cancer Growth

Xiangxiang Wu, Jamie L. Padilla, Lane E. Smith…·Xiang Xue

This study shows curcumin analogues HO-3867 and AKT-100 induce HMOX1-mediated ferroptosis and apoptosis, effectively inhibiting endometrial cancer cell growth.

3 citations

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintOct 6, 2025

The novel curcumin analogue AKT-100 targets both mutant p53 and STAT3 in gynecologic cancer cells

Geneva L. Williams, Lane E. Smith, Jamie L. Padilla…·Kimberly Kay Leslie

This paper develops AKT-100, a curcumin analogue that targets mutant p53 and STAT3 in gynecologic cancer cells, showing cytotoxicity and synergy with existing therapies.

1 citation

humanproteomics

𝕏 PostBluesky